Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study
Purpose We conducted a pilot trial to assess the tolerability, clinical benefit and antitumoral efficacy of modified (hydrolysed) citrus pectin (MCP) in 49 patients with various solid tumors in an advanced state of progression. MCP are hydrolysed from polysaccharide pectin fibers, derived from citru...
Main Authors: | Marc Azémar, Bernd Hildenbrand, Brigitte Haering, Manfred E. Heim, Clemens Unger |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2007-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S285 |
Similar Items
-
Citrus pectin modified by microfluidization and ultrasonication: Improved emulsifying and encapsulation properties
by: Wenjun Wang, et al.
Published: (2021-01-01) -
Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer
by: Sefora Conti MSc, et al.
Published: (2018-12-01) -
Characterization of Pectin Oligosaccharides Obtained from Citrus Peel Pectin
by: Diana Pasarin, et al.
Published: (2023-03-01) -
Isolation, characterization and modification of citrus pectins
by: MARIA KRATCHANOVA, et al.
Published: (2012-01-01) -
IntegroPectin: A New Citrus Pectin with Uniquely High Biological Activity
by: Rosaria Ciriminna, et al.
Published: (2021-10-01)